维普中文期刊产品整合服务
18篇 您的检索式:作者名="Neelapu"
    题名 作者 年代 出处 被引量
1Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lympboma显示文摘Schuster S J Neelapu SS Gause BL 0,,20:1
2Vaccine site inflam- mation potentiates idiotypc DNA vaccine-induced therapeu-tic T cell-, and not B cell-, dependent antilymphoma im- munity 显示文摘Qin H Cha SC Neelapu SS 2009Blood2009,114,19:1
3Transient state stress analysis on an axial flow gas turbine blades and disk using finite element procedure显示文摘BHATFI S K KUMARI S NEELAPU M L 2006WSEAS transactions on heat and mass transfer2006,1,3:1
4Vaccination with patient-specific tumor-derived antigen in first remission im- proves disease-free survival in follicular lymphoma显示文摘Schuster SJ Neelapu SS Gause BL 2011J Clin Oneol2011,29,20:1
5Lenalidomide and rituximab for untreated indolent lymphoma:nal results of a phase II study显示文摘Fowler NH Neelapu SS Hagemeister FB 2012Blood2012,120,:1
6Lenalidomide and rituximab for untreated indolent lymphoma:final results of a phase II study显示文摘Fowler NH Neelapu SS Hagemeister FB 2012ASH Annual Meeting Abstracts2012,120,:1
7Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen显示文摘NEELAPU SS BASKAR S GAUSE BL et nl 2004Clin Cancer Res2004,10,24:1
8A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma 显示文摘NEELAPU SS GAUSE BL HARVEY L 2007Blood2007,109,12:1
9Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma显示文摘NEELAPU SS KWAK LW KOBRIN CB 2005Nat Med2005,11,9:1
10Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial显示文摘Michael Wang Luis Fayad Nicolaus Wagner-Bartak Liang Zhang Fredrick Hagemeister Sattva S Neelapu Felipe Samaniego Peter McLaughlin Michelle Fanale Anas Younes Fernando Cabanillas Nathan Fowler Kate J Newberry Luhong Sun Ken H Young Richard Champlin Larry 2012Lancet Oncology2012,,:1
11Cancer imm unotherapy: strategies for personalization and combinatorial approaches显示文摘Sathyanarayanan V Neelapu S S 2015Mol Oncol2015,9,10:1
12Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with re- lapsed/refractory indolent lymphoma 显示文摘Cheah CY Nastoupil LJ Neelapu SS 2015Blood2015,125,21:1
13Phase 1 biomarker analysis ofthe ZUMA-1 ( KTE-C19-101 ) study : a phase 1-2 multi-center studyevaluating the safety and efficacy of anti-CD19 CAR T cells ( KTE-C19 ) in subjects with refractory aggressive non-Hodgkin lymphoma(NHL ) 显示文摘Rossi JM Neelapu SS Go WY 2015Blood ( ASH annual meeting Abstracts )2015,126,23:1
14Phase 1 clinical results ofthe ZUMA-1 (KTE-C19-101 ) study: a phase 1-2 multi-center studyevaluating the safety and efficacy of anti-CD 19 CAR T cells ( KTE-C19 ) in subjects with refractory aggressive non-Hodgkin lymphoma(NHL ) 显示文摘Locke FL Neelapu SS Bartlett NL 2015Blood ( ASH annual meeting Abstracts )2015,126,23:1
15Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines显示文摘 Neelapu SS Kwak LW 2002Haematologica2002,87,9:1
16Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission:phase Ⅲ clinical trial results显示文摘SCHUSTER S J NEELAPU S S GAUSE B L 2009J Clin Oncol2009,27,18:1
17Prospective phase II study of rituximab with alternating cycles of hyper‐ CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B ‐cell lymphoma显示文摘Yasuhiro Oki Jason R. Westin Francisco Vega Hubert Chuang Nathan Fowler Sattva Neelapu Fredrick B. Hagemeister Peter McLaughlin Larry W. Kwak Jorge E. Romaguera Michelle Fanale Anas Younes Maria Alma Rodriguez Robert Z. Orlowski Michael Wang Souzanne T. O 2013Br J Haematol2013,,5:1
18联合利妥昔单抗的人源化抗程序性死亡分子1单抗治疗复发滤泡性淋巴瘤的Ⅱ期临床试验:第54届美国血液学会年会深度报道显示文摘目的对进行的人源化抗人程序性死亡分子1(PD-1)单克隆抗体CT-011合并利妥昔单抗治疗复发性滤泡性淋巴瘤的Ⅱ期临床试验中,CT-011的安全性和效果进行评价。方法采集治疗前和注射CT-011第14天的30例患者外周血和恶性淋巴结活检标本,通过多参数流式细胞术分析外周血单个核细胞各个免疫细胞亚群的比例,使用QiagenRNeasy试剂盒从活检组织中抽提RNA,使用Illumina HumanRef-8基因芯片分析活检组织的基因表达图谱。结果治疗第14天外周血中淋巴细胞绝对数、CD;T细胞、CDiT细胞数量较治疗前显著增加;分析同时期活检组织的基因表达图谱发现一些和T细胞激活相关的基因表达上调。结论使用CT-011可使复发滤泡性淋巴瘤患者外周血和肿瘤微环境中的cD:T细胞增加和T细胞激活,显示出CT-011在临床治疗上具有令人鼓舞的应用前景。褚福亮 Westin JR 张明 靖彧 李亚芬 汤金乐 宗云辉 刘彬 Davis RE Neelapu SS 杨林 2013白血病.淋巴瘤2013,22,2:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费